Carotenoids as cancer preventive agents

Retinoids and Carotenoids in Dermatology

Volumn , Issue , 2007, Pages 307-331

  Bertram, John S ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79957647985     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (99)

1. Beecher GR, Khachik F. Qualitative relationship of dietary and plasma carotenoids in human beings. Ann N Y Acad Sci 1992; 669: 320-321.
2. Britton G. Structure and properties of carotenoids in relation to function. FASEB J 1995; 9(15): 1551-1558.
3. Means AL, Gudas LJ. The roles of retinoids in vertebrate development. Ann Rev of Biochem 1995; 64: 201-233.
4. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003; 3(4): 276-285.
5. Mathews-Roth MM. Carotenoids in erythropoietic protoporphyria and other photosensitivity diseases. Ann N Y Acad Sci 1993; 691: 127-138.
6. Lee EH, Faulhaber D, Hanson KM, et al. Dietary lutein reduces ultraviolet radiationinduced inflammation and immunosuppression. J Invest Dermatol 2004; 122(2): 510-517.
7. Mathews-Roth MM. Carotenoid pigment administration and delay in development of UV-B-induced tumors. Photochem Photobiol 1983; 37(5): 509-511.
8. Mathews-Roth MM, Krinsky NI. Carotenoid dose level and protection against UV-B induced skin tumors. Photochem Photobiol 1985; 42(1): 35-38.
9. Ponnamperuma RM, Shimizu Y, Kirchhof SM, De Luca LM. Beta-carotene fails to act as a tumor promoter, induces RAR expression, and prevents carcinoma formation in a two-stage model of skin carcinogenesis in male Sencar mice. Nutr Cancer 2000; 37(1): 82-88.
10. Steinel HH, Baker RS. Effects of beta-carotene on chemically-induced skin tumors in HRA/Skh hairless mice. Cancer Lett 1990; 51(2): 163-168.
11. Sies H, Stahl W. Carotenoids and UV protection. Photochem Photobiol Sci 2004; 3(8): 749-752.
12. Fung TT, Hunter DJ, Spiegelman D, Colditz GA, Speizer FE, Willett WC. Vitamins and carotenoids intake and the risk of basal cell carcinoma of the skin in women (United States). Cancer Causes Control 2002; 13(3): 221-230.
13. McNaughton SA, Marks GC, Gaffney P, Williams G, Green AC. Antioxidants and basal cell carcinoma of the skin: a nested case-control study. Cancer Causes Control 2005; 16(5): 609-618.
14. Fung TT, Spiegelman D, Egan KM, Giovannucci E, Hunter DJ, Willett WC. Vitamin and carotenoid intake and risk of squamous cell carcinoma of the skin. Int J Cancer 2003; 103(1): 110-115.
15. Frieling UM, Schaumberg DA, Kupper TS, Muntwyler J, Hennekens CH. A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician’s health study. Arch Dermatol 2000; 136(2): 179-184.
16. Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 1990; 323(12): 789-795.
17. Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354(9180): 723-729.
18. Hata TR, Scholz TA, Ermakov IV, et al. Non-invasive raman spectroscopic detection of carotenoids in human skin. J Invest Dermatol 2000; 115(3): 441-448.
19. Mayne ST. Beta-carotene, carotenoids, and disease prevention in humans. FASEB J 1996; 10(7): 690-701.
20. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature 1981; 290: 201-208.
21. Heinonen OP, Albanes D. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.
22. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996; 88(21): 1550-1559.
23. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334(18): 1145-1149.
24. Mayne ST, Cartmel B, Baum M, et al. Randomized trial of supplemental β-carotene to prevent second head and neck cancer. Cancer Res 2001; 61(4): 1457-1463.
25. Liu C, Russell RM, Wang XD. Exposing ferrets to cigarette smoke and a pharmacological dose of beta-carotene supplementation enhance in vitro retinoic acid catabolism in lungs via induction of cytochrome P450 enzymes. J Nutr 2003; 133(1): 173-179.
26. Liu C, Russell RM, Wang XD. Low dose beta-carotene supplementation of ferrets attenuates smoke-induced lung phosphorylation of JNK, p38 MAPK, and p53 proteins. J Nutr 2004; 134(10): 2705-2710.
27. Liu C, Lian F, Smith DE, Russell RM, Wang XD. Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res 2003; 63(12): 3138-3144.
28. Imaida K, Tamano S, Kato K, et al. Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis. Carcinogenesis 2001; 22(3): 467-472.
29. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: Review of the epidemiologic literature. J Natl Cancer Inst 1999; 91(4): 317-331.
30. Kolonel LN, Hankin JH, Whittemore AS, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000; 9(8): 795-804.
31. Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2004; 13(3): 340-345.
32. Kucuk O, Sarkar FH, Djuric Z, et al. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood) 2002; 227(10): 881-885.
33. Bowen P, Chen L, Stacewicz-Sapuntzakis M, et al. Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med (Maywood) 2002; 227(10): 886-893.
34. Mohanty NK, Saxena S, Singh UP, Goyal NK, Arora RP. Lycopene as a chemopreagent in the treatment of high-grade prostate intraepithelial neoplasia. Urol Onc2005; 23(6): 383-385.
35. Ansari MS, Gupta NP. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int 2003; 92(4): 375-378.
36. Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 2004; 64(16): 5891-5896.
37. Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW, Jr, Clinton SK. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J. Natl. Cancer Inst. 2003; 95 (21), 1578-1586.
38. Ben Dor, A, Steiner, M, Gheber, L, et al. Carotenoids activate the antioxidant response element transcription system. Mol Cancer Ther 2005; 4(1): 177-186.
39. Cohen LA, Zhao ZL, Pittman B, Khachik F. Effect of dietary lycopene on N-methylnitrosourea- induced mammary tumorigenesis. Nutr Cancer 1999; 34(2): 153-159.
40. Siler U, Barella L, Spitzer V, et al. Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB J 2004; 18(9): 1019-1021.
41. Siler U, Herzog A, Spitzer V, et al. Lycopene effects on rat normal prostate and prostate tumor tissue. J Nutr 2005; 135(8): 2050S-2052S.
42. Obermuller-Jevic UC, Olano-Martin E, Corbacho AM, et al. Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J Nutr 2003; 133(11): 3356-3360.
43. Hwang ES, Bowen PE. Cell Cycle Arrest and induction of apoptosis by lycopene in LNCaP human prostate cancer cells. J Med Food 2004; 7(3): 284-289.
44. Hantz HL, Young LF, Martin KR. Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med (Maywood) 2005; 230(3): 171-179.
45. Reznikoff CA, Bertram JS, Brankow DW, Heidelberger C. Quantitative and qualitative studies of chemical transformation of cloned C3H mouse embryo cells sensitive to postconfluence inhibition of cell division. Cancer Res 1973; 33: 2339-2349.
46. Merriman R, Bertram JS. Reversible inhibition by retinoids of 3-methylcholanthreneinduced neoplastic transformation in C3H10T1/2 cells. Cancer Res 1979; 39: 1661-1666.
47. Pung A, Rundhaug JE, Yoshizawa CN, Bertram JS. β-Carotene and canthaxanthin inhibit chemically- and physically-induced neoplastic transformation in 10T1/2 cells. Carcinogenesis 1988; 9: 1533-1539.
48. Cooney RV, Kappock TJ, Pung A, Bertram JS. Solubilization, cellular uptake, and activity of β-carotene and other carotenoids as inhibitors of neoplastic transformation in cultured cells. Methods Enzymol 1993; 214: 55-68.
49. Bertram JS, Pung A, Churley M, Kappock TJI, Wilkins LR, Cooney RV. Diverse carotenoids protect against chemically induced neoplastic transformation. Carcinogenesis 1991; 12: 671-678.
50. Bertram JS. The molecular biology of cancer. Mol Aspects Med 2001; 21: 167-223.
51. Victor VM, Rocha M, De La FM. Immune cells: free radicals and antioxidants in sepsis. Int Immunopharmacol 2004; 4(3): 327-347.
52. Baran CP, Zeigler MM, Tridandapani S, Marsh CB. The role of ROS and RNS in regulating life and death of blood monocytes. Curr Pharm Des 2004; 10(8): 855-866.
53. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000; 21(3): 361-370.
54. Ames BN, Shigenaga MK, Gold LS. DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis. Environ Health Perspect 1993; 101(suppl 5): 35-44.
55. Kuipers EJ, Meuwissen SG. Helicobacter pylori and gastric carcinogenesis. Scand J Gastroenterol Suppl 1996; 218: 103-105.
56. Nishino H, Jinno K. Prevention of hepatitis C virus-induced liver cancer by natural carotenoids and vitamin E. Proceedings of Frontiers in Cancer Prevention Research, AACR Conference 107, 202. 2002.
57. Watanabe S, Kitade Y, Masaki T, Nishioka M, Satoh K, Nishino H. Effects of lycopene and Sho-saiko-to on hepatocarcinogenesis in a rat model of spontaneous liver cancer. Nutr Cancer 2001; 39(1): 96-101.
58. Lee SJ, Bai SK, Lee KS, et al. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NFkappaB activation. Mol Cells 2003; 16(1): 97-105.
59. Gradelet S, Le Bon AM, Bergès R, Suschetet M, Astorg P. Dietary carotenoids inhibit aflatoxin B1-induced liver preneoplastic foci and DNA damage in the rat: role of the modulation of aflatoxin B1 metabolism. Carcinogenesis 1998; 19(3): 403-411.
60. Astorg P, Gradelet S, Leclerc J, Siess MH. Effects of provitamin A or non-provitamin A carotenoids on liver xenobiotic-metabolizing enzymes in mice. Nutr Cancer 1997; 27(3): 245-249.
61. Talalay P, Fahey JW, Holtzclaw WD, Prestera T, Zhang YS. Chemoprotection against cancer by Phase 2 enzyme induction. Toxicol Lett 1995; 82-83, 173-179.
62. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A 2002; 99(18): 11908-11913.
63. Astorg P, Gradelet S, Leclerc J, Canivenc M-C, Siess M-H. Effects of beta-carotene and canthaxanthin on liver xenobiotic-metabolizing enzymes in the rat. Food Chem Toxic 1996; 32: 735-742.
64. Aust O, Ale-Agha N, Zhang L, Wollersen H, Sies H, Stahl W. Lycopene oxidation product enhances gap junctional communication. Food Chem Toxicol 2003; 41(10): 1399-1407.
65. Ramos-Gomez M, Kwak MK, Dolan PM, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U. S A 2001; 98(6): 3410-3415.
66. Devling TW, Lindsay CD, McLellan LI, McMahon M, Hayes JD. Utility of siRNA against Keap1 as a strategy to stimulate a cancer chemopreventive phenotype. Proc Natl Acad Sci U S A 2005; 102(20): 7280A-7285A.
67. Neveu M, Bertram JS. Gap junctions and neoplasia. Adv Mol Cell Biol 2000; 30: 221-262.
68. Loewenstein WR. Cell-to-cell communication and the control of growth. Am Rev Respir Dis 1990; 142(suppl): S48-S53.
69. Nicholson BJ, Weber PA, Cao F, Chang H, Lampe P, Goldberg G. The molecular basis of selective permeability of connexins is complex and includes both size and charge. Braz J Med Biol Res 2000; 33(4): 369-378.
70. Mehta PP, Bertram JS, Loewenstein WR. Growth inhibition of transformed cells correlates with their junctional communication with normal cells. Cell 1986; 44: 187-196.
71. Hossain MZ, Wilkens LR, Mehta PP, Loewenstein WR, Bertram JS. Enhancement of gap junctional communication by retinoids correlates with their ability to inhibit neoplastic transformation. Carcinogenesis 1989; 10: 1743-1748.
72. Matesic DF, Rupp HL, Bonney WJ, Ruch RJ, Trosko JE. Changes in gap-junction permeability, phosphorylation, and number mediated by phorbol ester and nonphorbol- ester tumor promoters in rat liver epithelial cells. Mol Carcinogenesis 1994; 10: 226-236.
73. Beyer EC, Paul DL, Goodenough DA. Connexin family of gap junction proteins. J Membr Biol 1990; 116(3): 187-194.
74. Sohl G, Willecke K. An update on connexin genes and their nomenclature in mouse and man. Cell Commun Adhes 2003; 10(4-6): 173-180.
75. Zhang L-X, Cooney RV, Bertram JS. Carotenoids up-regulate connexin43 gene expression independent of their pro-vitamin A or antioxidant properties. Cancer Res 1992; 52: 5707-5712.
76. Bertram JS, Vine AL. Cancer prevention by retinoids and carotenoids: independent action on a common target. Biochim Biophys Acta 2005; 1740(2): 170-178.
77. Vine AL, Leung YM, Bertram JS. Transcriptional regulation of connexin 43 expression by retinoids and carotenoids: similarities and differences. Mol Carcinog 2005; 43(2): 75-85.
78. Zsila F, Simonyi M, Lockwood SF. Interaction of the disodium disuccinate derivative of meso-astaxanthin with human serum albumin: from chiral complexation to selfassembly. Bioorg Med Chem Lett 2003; 13(22): 4093-4100.
79. Zhang L-X, Cooney RV, Bertram JS. Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: relationship to their cancer chemopreventive action. Carcinogenesis 1991; 12: 2109-2114.
80. Hix LM, Lockwood SF, Bertram JS. Upregulation of connexin 43 protein expression and increased gap junctional communication by water soluble disodium disuccinate astaxanthin derivatives. Cancer Lett 2004; 211(1): 25-37.
81. Hix LM, Frey DA, McLaws MD, Osterlie M, Lockwood SF, Bertram JS. Inhibition of chemically-induced neoplastic transformation by a novel tetrasodium diphosphate astaxanthin derivative. Carcinogenesis 2005; 26(9): 1634-1641.
82. Daubrawa F, Sies H, Stahl W. Astaxanthin diminishes gap junctional intercellular communication in primary human fibroblasts. J Nutr 2005; 135(11): 2507-2511.
83. King TJ, Fukushima LH, Hieber AD, Shimabukuro KA, Sakr WA, Bertram JS. Reduced levels of connexin43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression. Carcinogenesis 2000; 21(6): 1097-1109.
84. King TJ, Fukushima LH, Yasui Y, Lampe PD, Bertram JS. Inducible expression of the gap junction protein connexin43 decreases the neoplastic potential of HT-1080 human fibrosarcoma cells in vitro and in vivo. Mol Carcinog 2002; 35(1): 29-41.
85. Zimmerman RJ, Little JB. Characterization of a quantitative assay for the in vitro transformation of normal human diploid fibroblasts to anchorage independence by chemical carcinogens. Cancer Res 1983; 43: 2176-2182.
86. Meyskens FL, Jr, Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-transretinoic acid: a randomized trial. J Natl Cancer Inst 1994; 86: 539-543.
87. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323(12): 795-801.
88. Garewal H, Meyskens F, Jr, Katz RV. B-carotene produces sustained remissions in oral leukoplakia: results of a 1 year randomized, controlled trial. Proc Am Soc Clin Oncol 1995; 14: 496.
89. Guo H, Acevedo P, Parsa DF, Bertram JS. The gap-junctional protein connexin 43 is expressed in dermis and epidermis of human skin: differential modulation by retinoids. J Invest Dermatol 1992; 99: 460-467.
90. Bertram JS, Bortkiewicz H. Dietary carotenoids inhibit neoplastic transformation and modulate gene expression in mouse and human cells. Am J Clin Nutr 1995; 62: 1327S-1336S.
91. Voskuil DW, Vrieling A, van’t Veer LJ, Kampman E, Rookus MA. The insulin-like growth factor system in cancer prevention: potential of dietary intervention strategies. Cancer Epidemiol Biomarkers Prev 2005; 14(1): 195-203.
92. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195(2): 127-137.
93. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003; 35(11-12): 694-704.
94. Parkin DM. International variation. Oncogene 2004; 23(38): 6329-6340.
95. Sell C. Caloric restriction and insulin-like growth factors in aging and cancer. Horm Metab Res 2003; 35(11-12): 705-711.
96. Karas M, Amir H, Fishman D, et al. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 2000; 36(1): 101-111.
97. Nahum A, Hirsch K, Danilenko M, et al. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27Kip1 in the cyclin E-cdk2 complexes. Oncogene 2001; 20(26): 3428-3436.
98. Goossens K, Esquenet M, Swinnen JV, Manin M, Rombauts W, Verhoeven G. Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNcaP prostatic adenocarcinoma cells. Mol Cell Endocrinol 1999; 155(1-2): 9-18.
99. Wang S, DeGroff VL, Clinton SK. Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nutr 2003; 133(7): 2367-2376.